Please login to the form below

Not currently logged in
Email:
Password:

BRVO

This page shows the latest BRVO news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment

BRVO, one of the two main types of retinal vein occlusion, is caused by blood clots in a branch of the main vein in the retina, leading to blood and fluid ... If left untreated, BRVO can significantly impact a person's vision. Within the next three

Latest news

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    Lilly says that, although 2011 and 2013 NICE guidance backs laser photocoagulation as a first-line treatment of visual impairment due to BRVO, clinical practice has since changed. ... NICE's next appraisal committee meeting on Eylea and its use in

  • Bayer's Eylea cleared for wider use in Europe Bayer's Eylea cleared for wider use in Europe

    macular oedema following branch retinal vein occlusion (BRVO), while more than 50% of patients in the Eylea arm gained at least three lines of vision. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common

  • Germany's IQWiG delivers bad news for Bayer’s Eylea Germany's IQWiG delivers bad news for Bayer’s Eylea

    Bayer has also filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion (BRVO), a leading cause

  • Bayer files eye drug Eylea for new use in EU Bayer files eye drug Eylea for new use in EU

    retinal vein occlusion (BRVO), a common cause of visual impairment in the elderly. ... BRVO is around three times more common than CRVO so could provide a further fillip to growth momentum if approved.

  • NICE backs new use for Bayer’s Eylea NICE backs new use for Bayer’s Eylea

    Lucentis has a slightly expanded indication, which also covers branch retinal vein occlusion (BRVO), although only if treatment involving the use of lasers to seal blood vessels in the eye has

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...